Jeil Pharmaceutical Appoints Hansangcheol as Co-CEO to Strengthen Responsible Management

Eldest Son of Chairman Han Seung-soo Appointed as Co-CEO of Jeil Pharmaceutical

Han Sang-chul has been appointed as co-CEO of Jeil Pharmaceutical.

Jeil Pharmaceutical announced on the 25th that its board of directors held a meeting and appointed Han Sang-chul as co-CEO. With this, Jeil Pharmaceutical has transitioned to a co-CEO system with professional manager Sung Seok-je as CEO and Han Sang-chul as co-CEO.

Newly appointed co-CEO Han Sang-chul is the grandson of the late Han Won-seok, the founder of Jeil Pharmaceutical, and the eldest son of Han Seung-soo. He majored in Industrial Engineering at Yonsei University and graduated from the Graduate School of Business Administration at the University of Rochester in the United States. He joined Jeil Pharmaceutical in 2006 as a manager, served as Executive Director of Marketing and Executive Director of Business Planning, was promoted to Vice President in 2015, and became President of Jeil Pharmaceutical in 2023. He has concurrently served as CEO of Jeil Pharma Holdings, the holding company of Jeil Pharmaceutical, since 2017.

New co-CEO Han Sang-chul is recognized for contributing to the company's growth and development by holding key positions necessary for management, focusing on new drug research and development, diversifying business, and promoting the discovery of new business opportunities.

In particular, Onconic Therapeutics, a new drug research and development subsidiary established under his leadership in 2020, is regarded as an important turning point for improving the business structure of Jeil Pharmaceutical, which was previously centered on product sales.

Onconic Therapeutics received approval last year for 'Jacubojeong,' a treatment for gastroesophageal reflux disease, as South Korea's 37th new drug, just four years after its establishment. The follow-up pipeline, a dual-target anticancer drug candidate 'Nesuparip,' is also progressing smoothly through Phase 2 clinical trials. Additionally, Jeil Pharmaceutical's self-developed oral diabetes treatment new drug 'JP-2266' is attracting attention as a promising pipeline. It is currently in Phase 2 clinical trials.

A Jeil Pharmaceutical official stated, "While maximizing the expertise of the co-CEOs, responsibility management to enhance corporate competitiveness will be strengthened."

This content was produced with the assistance of AI translation services.